Exclusive License and Development Agreement between Sorrento Therapeutics, Inc. and China Oncology Focus LimitedExclusive License and Development Agreement • November 25th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made and entered into as of this 3rd day of October, 2014 (“Effective Date”) between Sorrento Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America (“USA”) with its principal offices at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 US (“SORRENTO”), and China Oncology Focus Limited, a company organized and existing under the laws of British Virgin Islands with its registered office at Offshore Incorporations Centre, P.O. BOX 957, Road Town, Tortola, British Virgin Islands (“Lee’s”), an Affiliate of Lee’s Pharmaceutical Holdings Limited with a principal offices at Unit 110-111, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong.
